Abstract
Hypersensitivity pneumonitis (HP) is characterized by a lymphocytic alveolitis, classically delineated by an increase of CD8+ lymphocytes, with an inversion of the CD4+/CD8+ ratio. The aim of this study is both to describe the yield and cell bronchoalveolar lavage (BAL) profile and to revisit the assumption of low BAL CD4/CD8 ratio in the diagnosis of HP. A multicentric study was conducted on 139 patients who fulfilled the standardized diagnostic criteria of HP, mainly affected by farmers lung. Mean total cell count in BAL fluid was 594 ± 401.103 cells /ml. Prominent absolute lymphocytic alveolitis, moderate neutrophilia, and mild eosinophilia and mastocytosis were found. Mean CD4/CD8 ratio was 3.8 ± 6.1 (median 2.1). Thirty four percent of the patients showed lymphocytic CD8 alveolitis (ratio < 1). The CD4/CD8 ratio was not different between forms, etiologies of HP, and time elapsed since last antigen exposure, but was higher in women (p=0.02). BAL in HP shows high total cell and lymphocyte counts, moderate neutrophilia, and mild eosinophilia and mastocytosis. An absence of low CD4/CD8 ratio should not at all exclude diagnosis.
Keywords: Bronchoalveolar lavage, Extrinsic allergic alveolitis, Facs analyses, hypersensitivity pneumonitis, lymphocytes, occupational medicine, lymphocytic alveolitis, CD8+ lymphocytes, moderate neutrophilia, mild eosinophilia
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Current Drug Safety
Current Bioactive Compounds
Current Drug Safety
Current Drug Targets
Current Drug Safety
Current Drug Targets
Current Medicinal Chemistry
Current Drug Targets
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Current Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Current Pharmaceutical Biotechnology
Central Nervous System Agents in Medicinal Chemistry
Letters in Drug Design & Discovery
Central Nervous System Agents in Medicinal Chemistry
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Letters in Drug Design & Discovery
Current Drug Discovery Technologies
Recent Advances in Anti-Infective Drug Discovery
Current Drug Discovery Technologies
Recent Advances in Anti-Infective Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry
Recent Advances in Anti-Infective Drug Discovery
Anti-Cancer Agents in Medicinal Chemistry
Current Bioactive Compounds
Related Books
test ebook
Computer-Aided Drug Discovery Methods: A Brief Introduction
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Computer-Aided Drug Discovery Methods: A Brief Introduction
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Frontiers in Drug Design and Discovery
Medicinal Plants, Phytomedicines and Traditional Herbal Remedies for Drug Discovery and Development against COVID-19
Frontiers in Drug Design and Discovery
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Frontiers in Drug Design and Discovery
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part II
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Frontiers in Cardiovascular Drug Discovery
Key Heterocyclic Cores for Smart Anticancer Drug–Design Part I
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Cardiovascular Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Drug Design and Discovery
test ebook
Frontiers in Drug Design and Discovery
test ebook
Computer-Aided Drug Discovery Methods: A Brief Introduction
91